Developer protection provisions emerge as the final hurdle for the CLARITY Act
Svmuu News: According to a report by Crypto In America journalist Eleanor Terrett, bipartisan negotiations on the CLARITY Act in the U.S. Senate concluded last night without reaching an agreement. Senator Cynthia Lummis stated that lawmakers have agreed on 99% of the bill's content, but disputes remain unresolved over non-custodial developer BRCA protection clauses and ethics provisions related to the First Family, with the Banking Committee markup scheduled for tomorrow. Coin Center has drawn a red line, warning it will not support a watered-down BRCA proposal, calling this vote a "defining moment" for developer rights. As of now, the markup is expected to proceed along party lines, with the Democratic Party maintaining its opposition stance. (Bitcoin News)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
5
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
6
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
7
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
8
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
9
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
10
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
Markets Today
Recommended Reading






